Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Asset Writedowns and Impairment (2017 - 2021)

Celldex Therapeutics has reported Asset Writedowns and Impairment over the past 5 years, most recently at $3.5 million for Q3 2021.

  • Quarterly results put Asset Writedowns and Impairment at $3.5 million for Q3 2021, changed N/A from a year ago — trailing twelve months through Sep 2021 was $21.5 million (changed N/A YoY), and the annual figure for FY2021 was $3.5 million, down 80.56%.
  • Asset Writedowns and Impairment for Q3 2021 was $3.5 million at Celldex Therapeutics, down from $14.5 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for CLDX hit a ceiling of $14.5 million in Q4 2020 and a floor of $1.8 million in Q1 2019.
  • Median Asset Writedowns and Impairment over the past 5 years was $6.9 million (2018), compared with a mean of $7.9 million.
  • Peak annual rise in Asset Writedowns and Impairment hit 84.75% in 2019, while the deepest fall reached 84.75% in 2019.
  • Celldex Therapeutics' Asset Writedowns and Impairment stood at $13.0 million in 2017, then crashed by 47.1% to $6.9 million in 2018, then tumbled by 73.83% to $1.8 million in 2019, then skyrocketed by 705.56% to $14.5 million in 2020, then crashed by 75.86% to $3.5 million in 2021.
  • The last three reported values for Asset Writedowns and Impairment were $3.5 million (Q3 2021), $14.5 million (Q4 2020), and $3.5 million (Q2 2020) per Business Quant data.